Stefan Schmitz Selected Research

Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)

7/2007

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stefan Schmitz Research Topics

Disease

1	Malaria 01/2021
1	Carcinogenesis 12/2011
1	Hepatocellular Carcinoma (Hepatoma) 12/2011
1	Neoplasms (Cancer) 10/2007
1	Lymphoma (Lymphomas) 07/2007
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 07/2007

Drug/Important Bio-Agent (IBA)

1	Monoclonal AntibodiesIBA 01/2021
1	AntigensIBA 01/2021
1	VaccinesIBA 01/2021
1	Benzo(a)pyreneIBA 12/2011
1	Biomarkers (Surrogate Marker)IBA 12/2011
1	Bendamustine Hydrochloride FDA Link 07/2007
1	Rituximab (Mabthera)FDA Link 07/2007
1	Mitoxantrone (Novantrone)FDA LinkGeneric 07/2007

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 10/2007 - 07/2007
1	Therapeutics 01/2021
1	Immunotherapy 07/2007